AtCor swings to profit
AtCor Medical (ASX:ACG) has reported its second ever half-year profit for 1H13 thanks to revenue growth and cost-cutting.
AtCor Medical (ASX:ACG) swung to a 1H13 profit of $2.3 million thanks to strong sales of its SphygmoCor blood pressure monitoring device.
Sales revenue grew 43% year-on-year to $5.4 million, partly as a result of some major contract wins.
The launch of SphygmoCor XCEL, an upgraded version of AtCor’s central aortic blood pressure monitoring test, helped revenue grow 17% in Australia and New Zealand. Sales in the US meanwhile increased 54%.
But Asian sales declined - with AtCor blaming the lead time needed to secure SphygmoCor XCEL registration in key markets such as China and Japan - and European sales were flat.
Operating expenses fell 21% to $3.5 million. AtCor’s cash position at the end of the half-year improved to $2.1 million, from a positive cash flow.
Announcing its results, AtCor said it remained focused on growing its pharmaceutical clinical trial services business and pursuing partnership opportunities for SphygmoCor as a platform.
The half-year marked AtCor’s second ever six-month profit. AtCor reported a maiden profit of $180,000 in 1H09, but subsequently fell back into the red. For FY12, the company reported a net loss of $1.9 million, from 14% lower revenue of $6.4 million.
The 1H13 results are in line with unaudited figures provided in January.
AtCor (ASX:ACG) shares were trading unchanged at around 10c as of around 1 pm on Friday, up from 7.8c on Wednesday prior to the announcement.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
